NNC9204-1706

Last updated

NNC9204-1706 or NN9423 is a GLP-1/GIP/glucagon receptor triple agonist developed by Novo Nordisk. [1] [2] It was evaluated in a clinical trial; [3] [4] adverse effects such as "dose-dependent increases in heart rate and reductions in reticulocyte count, increases in markers of inflammation and hepatic disturbances, and impaired glucose tolerance at the highest dosages" meant that the drug was declared to have an inadequate safety profile and discontinued. [5]

References

  1. ↑ Jepsen, Mathies M.; Christensen, Mikkel B. (September 2021). "Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity". Expert Opinion on Emerging Drugs. 26 (3): 231–243. doi:10.1080/14728214.2021.1947240. ISSN   1744-7623. PMID   34176426. S2CID   235661514.
  2. ↑ Bergmann, Natasha Chidekel; Davies, Melanie J.; Lingvay, Ildiko; Knop, Filip K. (January 2023). "Semaglutide for the treatment of overweight and obesity: A review". Diabetes, Obesity and Metabolism. 25 (1): 18–35. doi:10.1111/dom.14863. ISSN   1462-8902. PMC   10092086 . PMID   36254579.
  3. ↑ Abdi Beshir, Semira; Ahmed Elnour, Asim; Soorya, Aadith; Parveen Mohamed, Affana; Sir Loon Goh, Sheron; Hussain, Nadia; Al Haddad, Amal H. I.; Hussain, Faizah; Yousif Khidir, Israa; Abdelnassir, Zainab (1 October 2023). "A narrative review of approved and emerging anti-obesity medications". Saudi Pharmaceutical Journal. 31 (10): 101757. doi:10.1016/j.jsps.2023.101757. ISSN   1319-0164. PMC   10497995 . PMID   37712012.
  4. ↑ Müller, Timo D.; Blüher, Matthias; Tschöp, Matthias H.; DiMarchi, Richard D. (2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews. Drug Discovery. 21 (3): 201–223. doi:10.1038/s41573-021-00337-8. ISSN   1474-1776. PMC   8609996 . PMID   34815532.
  5. ↑ Novikoff, Aaron; Müller, Timo D. (2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides. 165: 171003. doi: 10.1016/j.peptides.2023.171003 . ISSN   0196-9781. PMC   10265134 . PMID   36997003.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.